HBC recorded total operating revenues of NOK 68.4 million in the second quarter
of 2025, compared to NOK 80.4 million in the same period last year. Net
operating revenues were NOK 67.8 million, compared to NOK 72.2 million in the
same quarter last year. Total operating revenue for the first six months of
2025 was NOK 129.3 million (NOK 132.8 million).
EBITDA for the quarter was negative NOK 5.4 million, compared to NOK -2.0
million in Q2 2024. The first six months was negative NOK 25.3 million (NOK-
18.2 million) The Operational EBITDA* amounted to positive NOK 1.3 million,
compared to negative NOK 2.5 million same quarter last year, reflecting the
exclusion of non-recurring items such as restructuring costs (NOK 0.0 million),
clinical trial and R&D investments (NOK 4.9 million), and Berkåk project costs
(NOK 2.4 million). For the first six months the Operational EBITDA* amounted to
NOK -7.0 million (NOK-10.3 million).
Cash and cash equivalents decreased by NOK 3.9 million during the quarter,
reaching NOK 68.0 million at the end of Q2 2025, up from NOK 25.3 million a year
earlier. Including available credit lines, total liquidity ended at NOK 76.5
million as of 30 June, 2025.
Highlights in the second quarter:
* Human Nutrition B2B Sales increased 180% YoY to NOK 9.3m, driven by strong
demand in Europe, China, and Southeast Asia. OmeGo® and ProGo® continued to
lead product launches, supported by scientific validation.
* NYO3® International AS launched OmeGo® Full Spectrum Omegas in softgel
format at Vitafoods Europe, marking a major global milestone for HBC's human
nutrition franchise.
* ProGo® won the "Panpan Cup" Food Maker Award in China and was a finalist in
the NutraIngredients-USA Awards in the "healthy aging" category,
underscoring its strong market positioning in longevity and metabolic
health.
* Brilliant Salmon Oil now present in over 25 countries, with new listings in
Italy, Ireland, Taiwan, UAE, and Ecuador. Further distribution agreements in
Japan, Czech Republic, and Ukraine are progressing.
* Completion of CalGo® bone health study showing prevention of bone loss and
trend toward increased bone mass. NT-II(TM) preclinical analyses accepted for
peer-reviewed publication. Planning initiated for a ProGo® cognitive health
study in Alzheimer's.
Please find the HBC Q2 2025 Financial report attached.
For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare ASA:
HBC is a Norwegian consumer and pet health company founded on the core values of
sustainability, optimal utilization of natural resources and full traceability.
It upcycles the side streams of the salmon industry by taking fresh filleted
salmon and converting it from a waste product into ingredients to improve human
and pet health.
These ingredients are ProGo®, a mix of bioactive peptides and collagen, OmeGo®,
a whole salmon oil, with all the fatty acid fractions contained in fish, and
CalGo® / NT-II® salmon bone powder containing calcium hydroxyapatite and
undenatured collagen for bone and joint health.
HBC places scientific evidence at the forefront which has led to important
academic partnerships and the identification of unique health benefits. This
includes the demonstration of improved iron metabolism by boosting the body's
ability to take up and use iron resulting in increased energy and vitality with
ProGo® as well as the activation of the GLP-1 receptor with fat reduction in
overweight adults. OmeGo® has shown important immune health benefits including
recovery from viral infection and improved respiratory health and sleep in
adults troubled by particulate matter pollution. Finally, CalGo® has shown both
bone and joint health benefits to support healthy ageing and active lifestyles.
This work has also resulted in the granting of a number of patents protecting
these discoveries. It has also led to the discovery of potential therapeutics
and HBC has spun out a biotech-focused company, HBC Immunology (HBCI) has raised
external finance, and the lead program is in prostate cancer followed by ovarian
cancer. A separate molecule is targeted as an oral, steroid-sparing therapy for
asthma. HBC's headquarters are in Ålesund, Norway with branches in Oslo, London,
Zürich, New Jersey and Palo Alto.
HBC is listed on Oslo Stock Exchange with ticker "HBC".
*) Alternative Performance Measures are further described on p. 13 in the
financial report.
This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act